| pubmed-article:1799472 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0596382 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0008163 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:1799472 | lifeskim:mentions | umls-concept:C2827738 | lld:lifeskim |
| pubmed-article:1799472 | pubmed:dateCreated | 1992-4-17 | lld:pubmed |
| pubmed-article:1799472 | pubmed:abstractText | Alpha interferon has shown initial promise in the treatment of low-grade non-Hodgkin's lymphoma (NHL), especially with the nodular form of the disease. The present study enrolled 70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m2 subcutaneously three times a week). Among 63 evaluable patients, similar response rates (62.1% and 64.7% respectively) were recorded for the treatment arms. In patients receiving no maintenance therapy, those who received interferon alfa-2b during the induction phase showed a favourable trend in terms of incidence of relapse compared to those who had received chlorambucil alone. During maintenance therapy with interferon alfa-2b, no significant differences in the occurrence of relapse have yet been seen compared to patients on no maintenance therapy. A longer observation period is needed to make a definitive conclusion about the usefulness of interferon maintenance therapy and to evaluate further the effects of the combined schedule of chlorambucil and interferon induction on the duration of remission. | lld:pubmed |
| pubmed-article:1799472 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1799472 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1799472 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1799472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1799472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1799472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1799472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1799472 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1799472 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:SantiniGG | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:ChisesiTT | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:PorcelliniAA | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:VinanteOO | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:MorettiLL | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:CoserPP | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:ContuAA | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:SalvagnoLL | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:CongiuMM | lld:pubmed |
| pubmed-article:1799472 | pubmed:author | pubmed-author:RancanLL6th | lld:pubmed |
| pubmed-article:1799472 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1799472 | pubmed:volume | 27 Suppl 4 | lld:pubmed |
| pubmed-article:1799472 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1799472 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1799472 | pubmed:pagination | S31-3 | lld:pubmed |
| pubmed-article:1799472 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:meshHeading | pubmed-meshheading:1799472-... | lld:pubmed |
| pubmed-article:1799472 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1799472 | pubmed:articleTitle | Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group. | lld:pubmed |
| pubmed-article:1799472 | pubmed:affiliation | Department of Haematology, San Bortolo Hospital, Vicenza, Italy. | lld:pubmed |
| pubmed-article:1799472 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1799472 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1799472 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1799472 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
